[go: up one dir, main page]

MA42196A - Particules de fumarate de diméthyle et leurs compositions pharmaceutiques - Google Patents

Particules de fumarate de diméthyle et leurs compositions pharmaceutiques

Info

Publication number
MA42196A
MA42196A MA042196A MA42196A MA42196A MA 42196 A MA42196 A MA 42196A MA 042196 A MA042196 A MA 042196A MA 42196 A MA42196 A MA 42196A MA 42196 A MA42196 A MA 42196A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
dimethyl fumarate
fumarate particles
particles
dimethyl
Prior art date
Application number
MA042196A
Other languages
English (en)
Inventor
Pierre Boulas
Erwin Irdam
Shyam B Karki
William F Kiesman
Cheuk-Yui Leung
Yiqing Lin
Andrea Trementozzi
Peter Zawaneh
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA42196A publication Critical patent/MA42196A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA042196A 2015-06-17 2016-06-15 Particules de fumarate de diméthyle et leurs compositions pharmaceutiques MA42196A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562181061P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
MA42196A true MA42196A (fr) 2018-04-25

Family

ID=56292916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042196A MA42196A (fr) 2015-06-17 2016-06-15 Particules de fumarate de diméthyle et leurs compositions pharmaceutiques

Country Status (13)

Country Link
US (2) US11291642B2 (fr)
EP (1) EP3310341A1 (fr)
JP (2) JP2018517735A (fr)
KR (1) KR20180018711A (fr)
CN (1) CN107920997A (fr)
AU (2) AU2016279997B2 (fr)
CA (1) CA2989581A1 (fr)
EA (1) EA201890068A1 (fr)
HK (1) HK1254054A1 (fr)
IL (1) IL256296A (fr)
MA (1) MA42196A (fr)
MX (1) MX387092B (fr)
WO (1) WO2016205270A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318246A1 (en) * 2015-10-28 2018-11-08 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
JP6902043B2 (ja) * 2016-02-11 2021-07-14 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. フマル酸ジメチルを含む医薬ビーズ製剤
CN111163760A (zh) * 2017-10-02 2020-05-15 诺华股份有限公司 用于制备药物产品的方法
US11318682B2 (en) 2018-04-06 2022-05-03 Hewlett-Packard Development Company, L.P. Three-dimensional (3D) object printing based on build material permeability
JP7564805B2 (ja) * 2018-10-05 2024-10-09 アイエスピー インヴェストメンツ エルエルシー 水溶性セルロースエーテルを含有する平滑な高固形分フィルムコーティング組成物、その調製方法およびその使用方法
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
WO2020160323A2 (fr) * 2019-01-31 2020-08-06 Elektrofi, Inc. Formation et morphologie de particules
EP3941445A4 (fr) * 2019-03-20 2023-08-02 Lyndra Therapeutics, Inc. Capsules et enrobages de capsules pour formes posologiques à résidence gastrique
US20220192995A1 (en) * 2019-03-20 2022-06-23 Lyndra Therapeutics, Inc. Coatings for gastric residence dosage forms
EP4247354A4 (fr) * 2020-11-18 2025-02-19 Fb-Hrs, Llc Compositions contenant du dofétilide et de la mexilétine et leurs utilisations
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
EP4346796A4 (fr) 2021-06-04 2025-04-30 Zim Laboratories Limited Compositions à libération retardée de fumarate de diméthyle
US11590071B2 (en) * 2021-07-06 2023-02-28 King Abdulaziz University Injectable drug delivery implant composition and method of use thereof
WO2025072751A1 (fr) 2023-09-29 2025-04-03 Battelle Memorial Institute Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025090498A1 (fr) * 2023-10-23 2025-05-01 Isp Investments Llc Sels d'acides gras à chaîne moyenne encapsulés et formes posologiques solides orales dérivées de ceux-ci
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
DK1799196T3 (en) * 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
PL1981465T3 (pl) 2006-01-18 2016-03-31 Intec Pharma Ltd Metoda wytwarzania przyrządów do podawania środka przyjmowanego doustnie
CA2721493C (fr) * 2008-04-18 2017-11-28 Intec Pharma Ltd. Administration de medicament a retention gastrique carbicopa - levodopa
CN102369000A (zh) * 2009-01-09 2012-03-07 前进制药公司 包含一种或多种富马酸酯的药用组合物
CN109044985A (zh) * 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
US9422226B2 (en) * 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
WO2013076216A1 (fr) * 2011-11-24 2013-05-30 Synthon Bv Libération contrôlée de particules comprenant du diméthylfumarate
MX370785B (es) 2012-02-07 2020-01-06 Biogen Ma Inc Composiciones farmacéuticas que contienen fumarato de dimetilo.
WO2015042294A1 (fr) * 2013-09-18 2015-03-26 Xenoport, Inc. Compositions de nanoparticules de fumarate de diméthyle
IN2013MU03070A (fr) * 2013-09-25 2015-07-17 Glenmark Pharmaceuticals Ltd
EP3079663A1 (fr) * 2013-12-13 2016-10-19 Biogen MA Inc. Forme pharmaceutique à libération contrôlée pour administration une fois par jour de fumarate de diméthyle
WO2015130998A1 (fr) * 2014-02-28 2015-09-03 Banner Life Sciences Llc Capsules molles entériques à libération contrôlée d'esters de fumarate

Also Published As

Publication number Publication date
WO2016205270A1 (fr) 2016-12-22
US20220362195A1 (en) 2022-11-17
MX387092B (es) 2025-03-19
EA201890068A1 (ru) 2018-09-28
CA2989581A1 (fr) 2016-12-22
AU2016279997A1 (en) 2018-01-18
WO2016205270A8 (fr) 2017-01-19
MX2017016509A (es) 2018-08-16
AU2016279997B2 (en) 2021-10-21
US11291642B2 (en) 2022-04-05
KR20180018711A (ko) 2018-02-21
AU2022200155A1 (en) 2022-02-10
JP2018517735A (ja) 2018-07-05
US20190070143A1 (en) 2019-03-07
IL256296A (en) 2018-02-28
HK1254054A1 (zh) 2019-07-12
CN107920997A (zh) 2018-04-17
JP2022042512A (ja) 2022-03-14
EP3310341A1 (fr) 2018-04-25

Similar Documents

Publication Publication Date Title
MA42196A (fr) Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
ZA201802125B (en) Pharmaceutical composition and application thereof
MA50541A (fr) Formulations pharmaceutiques
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
DK3529248T3 (da) Farmaceutiske sammensætninger
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
EP3541385A4 (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
EP3316685A4 (fr) Compositions pharmaceutiques lyophilisées
MA49837A (fr) Compositions pharmaceutiques
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
DK3280447T3 (da) Farmaceutiske formuleringer
EP3337463A4 (fr) Formulations pharmaceutiques
EP3302483A4 (fr) Compositions pharmaceutiques et utilisation de celles-ci
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
PT3236938T (pt) Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol
KR101809800B9 (ko) 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물
EP3651800A4 (fr) Formulations pharmaceutiques hydrocompressées
EP3423041A4 (fr) Compositions pharmaceutiques
EP3528818A4 (fr) Compositions pharmaceutiques
MA42552A (fr) Compositions pharmaceutiques de flurbiprofène et de tramadol
MA43126A (fr) Compositions pharmaceutiques de fumarate de diméthyle
MA49625A (fr) Compositions pharmaceutiques
DK3558261T3 (da) Farmaceutiske sammensætninger omfattende safinamid